Download Databook
Download Sample
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
June 2025
The global single-cell biotherapeutics market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034. This surge is attributed to evolving consumer preferences and technological advancements reshaping the industry.
The single-cell biotherapeutics market is rapidly expanding because of advancements in proteomics, transcriptomics, and genomics, as well as increasing spending in research and development, fueling the growth of the market. North America dominated the market due to the strong presence of healthcare infrastructure, increasing funding, and the presence of biotech key players. Asia-Pacific is fastest fastest-growing region due to growing supportive government initiatives and expanding biotechnology sector.
The single-cell biotherapeutics market is growing rapidly due to its inclusion of various technologies such as encapsulation, molecular delivery, and electrical stimulation, which hold promise for augmenting drug delivery and improving cell therapies. Single-cell biotherapeutics possess noteworthy potential for elucidating disease pathogenesis, detecting drug targets, emerging innovative therapies, and augmenting applications of stem cells. Single-cell biotherapeutics have become a vital tool in the development of cell-based drug delivery systems and innovative cell therapies. This biotherapeutic provides powerful means to address cellular heterogeneity and pointedly improves therapeutic efficacy. Also, provide significant insights into the complex disease mechanisms, the development of drug resistance, and the intricate processes of differentiation of stem cells.
AI integration in single-cell biotherapeutics drives the growth of the market as AI-driven technology incorporates with single-cell biotherapeutics, signifying a promising opportunity in biomedical research, providing an advanced way to improve data analysis, understanding, and eventually, the precision of biological insights. Artificial intelligence (AI) has seen huge advancements, offering powerful tools capable of analyzing high-dimensional information, discovering patterns, and making estimates that were previously unachievable. AI-based techniques also integrate single‐cell omics data, allowing robust disease and disease‐stage prediction, along with biomarker discovery. By analysing patients' medical histories, genetic profiles, and molecular data, AI helps design highly targeted cell therapies tailored to the precise characteristics of the patient.
Increasing Incidence of Infectious Diseases
The rising incidence of infectious diseases, notably diarrheal diseases, neonatal disorders, lower respiratory infections, and tuberculosis, leads to increasing mortality rates. Techniques like Next-Generation Sequencing (NGS) and Fluorescence-Activated Cell Sorting (FACS) provide significant insights into the relationship between cellular heterogeneity and the advancement of infectious diseases. Various single-cell technologies are being utilized in the continuous battle against these diseases. The integration of single-cell technologies is poised to transform clinical research for both therapeutics and vaccines, given its vast potential for identifying biomarkers, which is fueling the growth of the single-cell biotherapeutics market.
Single-Cell Requires Individual Reactions
Single-cell sequencing necessitates individual reactions for each cell, leading to a higher requirement for reagents compared to bulk experiments. Typically, the cost of reagents for standard single-cell RNA sequencing is 10 to 20 times greater than that of similar bulk RNA experiments, thereby constraining the expansion of the single-cell biotherapeutics market.
Recent Advancements in Technology
Single-cell technology (SCT) has become a pivotal tool, especially in biology, allowing for the analysis of the basic units that make up biological organs, tissues, and cells, and it significantly influences stem cell research. This cutting-edge technology paves the way for cell-specific data acquisition and enhances understanding of the molecular pathways that regulate organ function and biology. SCT is often utilized to investigate rare and diverse cell types, including stem cells, revealing the complexities of cellular diversity and dynamics. This perspective is vital for advancing stem cell research, enabling non-invasive examinations of molecular dynamics and cellular functions over time, thereby creating opportunities for the single-cell biotherapeutics market.
By product type, the consumables & reagents segment dominated in the single-cell biotherapeutics market in 2024, as single-cell biotherapeutics consumables & reagents differ extensively in stability, cost, need for cold or cool-chain, availability, and the risks associated with every variant. They are designed to aid researchers in increasing new cells in the culture media for the development of single-cell biotherapeutics.
The software & data analysis tools segment is expected to grow at the fastest CAGR over the forecast period, 2025 to 2035, as it plays a significant role in progressing treatments that involve gathering data of patients' treatment for medical purposes. Single-cell biotherapeutics software permits users to exploit efficiencies and stay informed on novel pathways of medicine. This software offers a central repository for all relevant data, confirming data integrity and making it simple to analyze and access information.
By therapeutic application, the oncology segment is dominant in the single-cell biotherapeutics market in 2024, as modern progress in the application of single-cell technologies towards gaining a profound understanding of intratumor evolution and heterogeneity. Single-cell technology offers the ability to identify rare cancer cells, like cancer stem cells (CSCs) and circulating tumor cells (CTCs)
The neurology segment is expected to grow at the fastest CAGR over the forecast period, 2025 to 2035, as single-cell ribonucleic acid sequencing (scRNA-seq) has developed as an innovative technology in neurosurgical and neurological research, revolutionising comprehension of multifaceted neurological disorders. Single-cell expression profiling can potentially be used to evaluate and discover therapeutic interventions for neurological disease.
By technology, the single-cell RNA sequencing (scRNA-seq) segment is dominant in the single-cell biotherapeutics market in 2024, as the single-cell biotherapeutics methods allow researchers to define cell-type-specific gene expression and multiomic data, determining the cellular heterogeneity that drives the expression patterns from bulk RNA-seq. Single-cell sequencing also identifies immune cells with high heterogeneity caused by pathogens, precisely detects the genetic material of separate immune cells, and helps to understand the multifaceted immune mechanism of the body.
The CRISPR screening at the single-cell level segment is expected to fastest-growing over the forecast period 2025 to 2035, as CRISPR screens are a significant source of biological discovery, allowing the impartial interrogation of gene function in an extensive range of applications and species.
By disease indication, the cancer segment is dominant in the single-cell biotherapeutics market in 2024, as single-cell technology powered by next-generation sequencing (NGS), which inspects the transcriptomes or genomes of individual cancer cells, offering a high-resolution view of cell-to-cell differences. Single-cell technologies are known as modern and powerful tools to study cancer biological systems at the single-cell resolution.
For Instance,
The rare genetic disorders segment is expected to grow at the fastest CAGR over the forecast period, as single-cell biotherapeutics signify a powerful tool for advancing understanding related to rare diseases, predominantly metabolic RDs, and renovating clinical practice. Continuous research and technological developments in single-cell metabolomics are significant for realizing its full potential in the sectors of rare genetic disorders therapeutics and diagnosis.
By end user, the pharmaceutical & biotechnology companies segment is dominant in the single-cell biotherapeutics market in 2024, as single-cell biotherapeutics, containing delivery of molecules, encapsulation, and electrical stimulation, for targeting drug delivery, and improving cell therapies in pharmaceutical and biotechnology organizations. Single-cell technologies are a next-generation sequencing method involving single-cell isolation, transcriptome characterization, and generation of a sequencing library.
The academic & research institutes segment is expected to fastest-growing over the forecast period 2025 to 2035, as it is actively involved in single-cell studies, by applications of advanced technologies to examine the difficulties of individual cells. These studies span different sectors, including immunology, cancer research, and developmental biology.
North America is dominant in the single-cell biotherapeutics market with the largest revenue share, due to modern technological advancements that have huge potential to enhance healthcare results, provided clinicians and patients adopt them. North Americans are early gain access to major novel healthcare developments, advances often discovered at North American universities and developed by North American companies. America’s revolutionary health care sector is the largest in the world, and includes major biotech key players such as Biogen, Genentech, and Amgen, along with medical device leaders Johnson & Johnson, Medtronic, and Boston Scientific, which contribute to the growth of the market.
For Instance,
In the United States, improving diagnostics technology in healthcare in each ways, from accuracy to speed to accessibility. It plays a significant role in addressing most of the biggest issues in healthcare. Adoption of modern technologies such as artificial intelligence speeds up drug discovery and assists with imaging analysis, lending to a growing requirement for innovation and management of all the different technologies, including single-cell biotherapeutics.
Canada’s medical care sector is renowned globally for its public health insurance program, ensuring all Canadians have access to essential medical services. Increasing government spending on health research in recent years has enabled Canada to capitalize on vital health advances and discoveries. In Canada, increasing demand for various therapies, for treating different conditions, drives the demand for the market.
The Asia Pacific region is projected to experience the fastest growth in the market during the forecast period, due to the continued increasing healthcare research and technology advances, and the expanding scope of precision medicine, which is increasing the demand for single-cell biotherapeutics solutions. Cell therapies are gaining momentum in Asia-Pacific, driven by increasing patient demand and a booming innovation ecosystem. This region is a hub of almost 600 AI healthcare start-ups, many of which are based in China, Australia, Singapore, and Japan, which drives the market growth.
In China, the government is increasing the biotherapeutics clinical trial approval process, making it effective and attractive to researchers and pharmaceutical companies. China has a huge, simply accessible patient population of 1.3 billion people and 15 megacities, along with populations exceeding 10 million people, offering novel opportunities to test and validate biotherapeutics services. Increasing regulatory health inputs, health insurance expansion, and improving public hospitals and the healthcare sector drive market growth.
India's medical care sector is undergoing a revolutionary shift, along with real estate emerging as a vigorous force driving the advancement of healthcare infrastructure. Recent modern technology, like digitized patient records, telemedicine, and smart infrastructure, is increasing patient care and enhancing the efficiency of operations. Growing India’s middle-class population grows, it grows disposable income. This leads to a corresponding surge in the demand for advanced quality healthcare solutions. The Indian government has implemented different incentives and policies to promote spending in the healthcare sector. Initiatives such as the National Health Policy and Ayushman Bharat contribute to the growth of the market.
Europe is expected to grow significantly in the market during the forecast period, as an increasing transformative single-cell data-driven approach has the potential to increase the success rates of clinical trials and the effectiveness of novel therapeutic interventions in clinics and hospitals of Europe over the next decade, which increases the demand for single-cell biotherapeutics solution.
In April 2025, Belén Garijo, Chair of the Executive Board and CEO of Merck, “Merck to Acquire US Biopharma Company SpringWorks Therapeutics It is a major step in our active portfolio strategy to position Merck as a globally diversified, innovation and technology powerhouse. For our Healthcare sector, it sharpens the focus on rare tumors, accelerates growth, and strengthens our presence in the U.S.” (Source - Merck)
By Product Type
By Therapeutic Application
By Technology
By Disease Indication
By End Use
By Region
June 2025
June 2025
June 2025
June 2025